LONDON, UK I October 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III clinical trials ANCHOR-1 and ANCHOR-2, ...
CAMBRIDGE, MA, USA & MONTREAL, Canada I October 14, 2024 I Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage ...
VALBY, Denmark & LA JOLLA, CA, USA I October 14, 2024 I H. Lundbeck A/S (Lundbeck) and Longboard Pharmaceuticals, Inc (NASDAQ: LBPH) (Longboard) today ...
NEW YORK, NY, USA I October 11, 2024 I Pfizer Inc. (NYSE: PFE)announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ ...
Approval is based on Phase III INAVO120 results, showing the ItovebiTM (inavolisib)-based regimen more than doubled progression-free survival compared with ...
COPENHAGEN, Denmark I October 10, 2024 I Novo Holdings, a leading global life sciences investor, today announced the launch of Booster Therapeutics (Booster / the Company), a biotechnology company ...
NEW YORK, NY, USA I October 10, 2024 I Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) ...
VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program’s ...
October 10, 2024 I Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients ...
PHILADELPHIA, PA, USA I October 08, 2024 I GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III ...